Navigation Links
Pharmaxis' Aridol Authorised for Sale in Germany
Date:5/18/2008

SYDNEY, Australia, May 18 /Xinhua-PRnewswire-Firstcall/ -- Specialist Pharmaceutical Company Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) today announced that it has received national approval to market Aridol in Germany.

Aridol is indicated for measuring airway hyperresponsiveness and has been approved in 14 European countries under the mutual recognition procedure (MRP). The necessary national approvals that follow the MRP have now been received for Denmark, Germany, Ireland, The Netherlands, Portugal, Sweden, and the United Kingdom.

In Germany a total of 660,000 lung function tests are conducted annually, of which approximately 90% are conducted by office-based physicians and the remainder in the major hospitals. To enter the market, Pharmaxis will first negotiate with insurance companies that cover the office-based physician market before launching with a local distributor.

A simple-to-use airways inflammation test, Aridol is a dry powder administered to patients' lungs via a small hand-held inhaler. Doctors can use the results of this test to identify airway hyperresponsiveness -- a hallmark of asthma. Medications can be adjusted according to the severity of the disease. (see overleaf for more details on Aridol)

"We are pleased that Aridol is becoming globally recognised as a useful test for identifying airway hyperresponsiveness," said Pharmaxis CEO Dr Alan Robertson. "With this latest approval, Aridol is on the way to becoming the worldwide standard for detecting sensitive airways in people with conditions such as asthma.

"The Aridol test provides objective information on airway hyperresponsiveness and assists in the diagnosis and assessment of severity of asthma and how much medication should be used."

As well as being included as one of the tests recommended by the International Olympic Committee -- Medical Commission Independent Panel and the World Anti-Doping Agency, Aridol is also included in the GINA Report of
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
3. Pharmaxis Closes Share Purchase Plan
4. Pharmaxis Appoints Portuguese Distributor for Aridol
5. Pharmaxis Aridol Gains First Asian Approval
6. Pharmaxis Investor Conference Call
7. Pharmaxis to Apply to Market Bronchitol in Australia
8. Pharmaxis First Steps into China
9. Aridol(TM) Endorsed by International Olympic Committee
10. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
11. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MESSENGER has just celebrated its 10 year anniversary in ... of its latch valves, V27200-818, operating onboard this spacecraft. ... the planet Mercury. It is only the second spacecraft ... vast amount of information and images of the planet. ... that also include permanent magnets to maintain the valve ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... a deicing film for radar domes have now refined ... glass. , The new work by Rice chemist ... from windshields to skyscrapers free of ice and fog ... , The technology was introduced this month in the ... . , The material is made of graphene ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... -- As open enrollment season approaches, U.S. employees will soon ... benefits. According to Aon Hewitt , the global ... plc (NYSE: AON ), employees will ... managing their health care decisions. This increased responsibility makes ... how they can make the most of the programs ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7
... "crack baby" hysteria of the 1980s was greatly ... but disabling cognitive impairments -- attention deficits, learning ... study by investigators at the Vanderbilt Kennedy Center ... the long-term behavioral and neurological problems associated with ...
... especially those that are hydrophobic or water-repellant, to tumors ... develop innovative delivery systems that keep these drugs intact ... University at Buffalo’s Institute for Lasers, Photonics and Biophotonics ... solution in which the delivery system is the drug ...
... Researchers have linked a structural protein called nestin to ... new biomarker that could lead to earlier detection and ... of Cancer Research, researchers from Dartmouth Medical School demonstrate ... basal epithelial breast tumors, a highly aggressive cancer with ...
Cached Biology News:Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3No carrier necessary: This drug delivers itself 2Selective marker found to indicate aggressive form of breast cancer 2
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
... Fragment is a genetically engineered Klenow polymerase in ... been removed, leaving only the 5 to 3 ... Exo- Klenow Fragment the enzyme of choice for ... the random primed method, and for DNA sequencing ...
... RNA polymerase is a DNA-dependent RNA polymerase ... promoters. It efficiently synthesizes in vitro ... down stream from a T7 promoter. ... templates for in vitro translation, substrates in ...
Biology Products: